CEL-SCI's Phase 3 Population Analysis For Confirmatory Registration Study In Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence In Clinical Results; Multikine, A Cancer Immunotherapy, Cut The 5-Year Risk Of Death By Half Compared To Control In Its Target Population
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI Corporation (NYSE:CVM) reported positive results from a bias analysis for its Phase 3 study of Multikine, a cancer immunotherapy for head and neck cancer. The analysis showed no bias, supporting the efficacy results, and Multikine cut the 5-year risk of death by half compared to control.
July 26, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI Corporation's Phase 3 study of Multikine showed no bias and demonstrated a significant reduction in the 5-year risk of death for head and neck cancer patients. This supports the efficacy of Multikine and boosts confidence in its upcoming regulatory submissions.
The positive bias analysis results and significant reduction in the 5-year risk of death bolster the efficacy claims of Multikine. This is likely to positively impact CEL-SCI's stock price in the short term, especially with upcoming regulatory submissions.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100